The pineal gland as a central regulator of cytokine network

Neuroendocrinology Letters

Volumn 20, Issue 6, 2000, Pages 343-349

  Lissoni, Paolo ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Cytokines; Melatonin; Neuroimmunomodulation; Pineal gland

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2; MELATONIN; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; ENDOCRINE FUNCTION; FEEDBACK SYSTEM; HELPER CELL; HORMONE RELEASE; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY DISEASE; PATHOPHYSIOLOGY; PINEAL BODY; PSYCHOLOGICAL ASPECT; REVIEW; T LYMPHOCYTE;

EID: 0033981415     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Shrivastava A, Aggarwal BB. Cytokines as biological regulators of homeostasis. J Biol Regul Homeost Agents 1998; 12:1-24.
2. Jankovic BD. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann NY Acad Sci 1994; 741:1-38.
3. Brzezinski A. Melatonin in humans. N Engl J Med 1997; 336: 186-195.
4. Del Gobbo V, Libri V, Villani N, Callo R, Nisticò G. Pinealectomy inhibits interleukin-2 production and natural killer activity in mice. Int J Immunopharmacol 1989; 11:567-571.
5. Lissoni P, Barni S, Archili C, Cattaneo G, Rovelli F, Conti A, et al. Endocrine effects of a 24-hour intravenous infusion of interleukin-2 in the immunotherapy of cancer. Anticancer Res 1990; 10:753-758.
6. Maestroni GJM. The immunoendocrine role of melatonin. J Pineal Res 1993;14:1-10.
7. Lissoni P, Pittalis S, Barni S, Rovelli F, Fumagalli L; Maestroni GJM. Regulation of interleukin-2/interleukin-12 interactions by the pineal gland. Int J Thymol 1997; 5:443-447.
8. Braczkowski R, Zubelewicz B, Romanowski O, Mazurkieicz E, Lissoni P, Rovelli F. Restoration of the melatonin circadian rhythm after h-rec-TNF-alpha therapy in patients with advanced cancer. Polish J Endocrinol 1996; 47:375-381.
9. Zylinska K, Komorowski J, Robak T, Mucha S, Stepien H. Effect of granulocyte-macrophage colony stimulating factor and granulocyte colony stimulating factor on melatoni secretion in rats in vivo and in vitro studies. J Neuroimmunol 1995; 56:187-190.
10. Lissoni P. Prognostic markers in interleukin-2 therapy. Cancer Biother Radiopharm 1996; 11:285-287.
11. Clerici M, Clerici E. The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst 1996; 88:461-462.
12. Del Prete G. Human Th1 and Th2 lymphocytes: their role in the pathophysiology of atopy. Allergy 1991; 47:450-455.
13. Jasnosky ML, Kugler J. Relaxation, imagery and neuroimmunomodulation. Ann NY Acad Sci 1987; 496:722-730.
14. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998; 62:583-606.
15. Grugni G, Granata A, De Medici C, Ardizzi A, Guzzaloni G, Baldini A, et al. Effects of erotic visual stimulation on melatonin serum levels. J Endocrinol Invest 1994; 17 (suppl 1):36.
16. Rubinow DR. Brain, behaviour and immunity: an interactive system. J Natl Cancer Inst Monogr 1990; 10:79-82.
17. Payne LC, Krueger JM. Interactions of cytokines with the hypothalamus-pituitary axis. J Immunother 1992; 12:171-173.
18. Besedovsky H, Del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feed-back between interleukin-1 and glucocorticoid hormones. Science 1986; 233:652-654.
19. Elenkov IJ, Papanicolaou DA, Wilber RL, Chrosous GP. Modulatory effects of glucocorticoid and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Ass Am Phys 1996; 108:374-381.
20. Sacerdote P, Panerai AE. Role of opioids in the modulation of TH1/ TH2 responses. Neuroimmunomodulation 1999; 6:422-423.
21. Banks RE, Patel PM, Selby PJ. Interleukin-12: a new clinical player in cytokine therapy. Br J Cancer 1995; 71:655-659.
22. Klein TW, Newton C, Friedman H. Cannabinoid receptors and immunity. Immunol. Today 1998; 19:373-381.
23. Atzpodien J, Kirchner H. Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 1990; 68:1-11.
24. Whittington R, Faulds D. Interleukin-2. Drugs 1993; 46:446-514.
25. Lotze MT, Hellerstedt B, Stolinski L, Tueting T, Wison C, Kinzler D, et al. The role of interleukin-2 interleukin-12 and dendritic cells in cancer therapy. Cancer J Sci Am 1997; 3:S109-S114.
26. Naor D, Duke-Cohan JS. Suppressor cells and malignancy; I) Suppressor macrophages and suppressor T cells in experimental animals. In: Ray PK, editor. Advances in immunity and cancer therapy, vol 2. Springer Verlag, New York, 1986 pp. 9-96.
27. Tanner J, Tosato G. Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 1991; 88:239-247.
28. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. Soluble interleukin-2 receptors abrogate IL-2-induced activation of peripheral mononuclear cells. Cytokine 1994; 6:358-364.
29. Jankovic BD, Isakovic K, Petrovic S. Effect of pinealectomy on immune reactions in rat. Immunology 1970; 18:1-3.
30. Guerrero JM, Reiter RJ. A brief sumrrary of pineal-immune system inter-relationship. Endocr Res 1992; 18:91-113.
31. Martins E, Skorupa AL, Cipolla-Neto J, Costa-Rosa LFBP. Synthesis of melatonin by macrophages and lymphocytes in pinealectomized rats. Neuroimmunomodulation 1999; 6:449.
32. Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJM. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin. J Biol Regul Homeost Agents 1997; 11:119-122.
33. Lissoni P, Mandalà M, Mandelli A, Fumagalli L. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 plus the pineal oncostatic hormones melatonin and 5-methoxytryptamine in untreatable advanced solid neoplasms patients with poor clinical status. Int J Immunother 1999; XV:35-38.
34. Carrillo-Vico A, Garcia-Maurino S, Pczo D, Camvo JR, Guerrero JM. Melatonin activates Th1 lymphocytes by increasing IL-12 production. Neuroimmunomodulation 1999; 6:448.
35. Lissoni P, Paolorossi F, Tancini G, Barni S, Ardizzoia A, Brivio F, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A:1340-1343.
36. Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, et al. A randomised study with subcutaneous low-dose interleukin-2 vs. interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994; 69:196-199.
37. Bartsch C, Barsch E, Lippert TH. The pineal gland and cancer: facts, hypotheses and perspectives. Cancer J 1992; 5:194-199.
38. Bartsch C, Barsch E, Lippert TH. Rationale to consider the use of melatonin as a chrono-oncotherapeutic drug. In vivo 1995; 9: 305-310.
39. Vinnitsky VB. Oncogerminative hypothesis of tumor formation. Med Hypotheses 1993; 40:19-27.
40. Feychting M, Osterlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology 1998; 9:490-494.
41. Kroeker G, Parkinson D, Vriend J, Peeling T. Neurochemical effects of static magnetic field exposure. Surg Neurol 1996; 45: 62-66.
42. Viviani S, Bidoli P, Spinazzé S, Rovelli F, Lissoni P. Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small-cell lung cancer. J Pineal Res 1992; 12:114-117.
43. Battistini B, Chailler P, D'Orléans-Juste P, Brière N, Sirois P. Growth regulatory properties of endothelins. Peptides 1993; 14: 385-399.
44. Kenneth G. Physiology and pathophysiology of atrial peptides. Am J Physiol 1988; 254:E1-E15.
45. Lissoni P, Pittalis S, Vigoré L, Rovelli F, Vezzo R, Bramati S, et al. The heart as an immimomodulator organ: in vitro effects of atrial natriuretic peptide-alpha and their possible relevance in cardiac failure and aging. Cardiol Elder 1993; 1:227-231.
46. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumor inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-1103.
47. Asham EH, Loizidou M, Taylor I. Endothelin-1 and tumor development. Eur J Surg Oncol 1998; 24:57-60.
48. Zinman T, Salzberg S, Malik Z, Shainberg A. Inhibition of malignant cell proliferation by culture media conditioned by cardiac or skeletal muscle. Cell Biol Int 1997; 21:133-137.
49. Axelrod J. The pineal gland: a neurochemical transducer. Science 1974; 184:1341-1348.
50. Lissoni P, Pelizzoni F, Grugni G, Guzzaloni G, Mauri O, Archili C, et al. Melatonin response to atrial natriuretic peptide in healthy volunteers. J Cardiovasc Pharmacol 1990; 16:850-852.
51. Sparks DL, Hunsaker JC. The pineal gland in sudden infant death syndrome: preliminary considerations. J Pineal Res 1988; 5:111-118.